Suppr超能文献

外泌体传递的HSPA9通过靶向多发性骨髓瘤中的TRIP13/USP1信号通路促进硼替佐米耐药。

Exosome-transmitted HSPA9 facilitates bortezomib resistance by targeting TRIP13/USP1 signaling in multiple myeloma.

作者信息

Shi Min, Shen Na, Liu Xiangyu, Yu Jiapei, Shen Xuxing, Chen Ying, Xia Yuan, Chen Lijuan

机构信息

Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.

出版信息

Cell Commun Signal. 2025 Mar 26;23(1):152. doi: 10.1186/s12964-025-02158-3.

Abstract

BACKGROUND

Resistance to the proteasome inhibitor bortezomib (BTZ) poses a formidable therapeutic challenge in multiple myeloma (MM). Our study aims to analyze the mechanism by which exosomes heat shock 70 kDa protein 9 (HSPA9) secreted by BTZ-resistant MM cells disseminate resistance to BTZ-sensitive MM cells.

METHODS

The serum exosomes were identified by nanoparticle tracking analysis and transmission electron microscopy. Liquid chromatography-mass spectrometry and public databases were performed to screen exosomes HSPA9. Cell counting kit-8, western blotting and colony formation assay were used to detected the role of HSPA9 protein in vitro. Co-immunoprecipitation, immunofluorescence and protein truncation test experiments were used to determine the regulatory network of the HSPA9-USP1-TRIP13 complex. Optical imaging in vivo and xenograft mouse models were performed to investigate that exosomes HSPA9 promoted MM proliferation and BTZ resistance.

RESULTS

We demonstrated that HSPA9 was highly expressed in serum exosomes and BTZ-resistant MM patients. Knockdown of HSPA9 significantly suppressed tumorigenesis and reversed BTZ resistance in vitro. As a downstream molecular of HSPA9, thyroid hormone receptor-interacting protein 13 (TRIP13) was also highly expressed in BTZ-resistant MM patients. Mechanistically, the carboxyl-terminal peptide-binding domain of HSPA9, provides a platform for recruiting the deubiquitinating enzyme ubiquitin-specific peptidase 1 (USP1), which prevents TRIP13 protein degradation. The HSPA9-USP1-TRIP13 complex exhibits stability in the cytoplasm, and its inhibition remarkably enhances BTZ resistance in vito.

CONCLUSION

Our findings propose a pioneering molecular regulatory network in which MM-cell-derived exosomes HSPA9 transmitted BTZ resistance through the USP1/TRIP13 signaling pathway. This research highlights exosomes HSPA9 as a promising target to overcome MM BTZ resistance.

摘要

背景

对蛋白酶体抑制剂硼替佐米(BTZ)产生耐药性给多发性骨髓瘤(MM)带来了严峻的治疗挑战。我们的研究旨在分析BTZ耐药的MM细胞分泌的外泌体热休克70 kDa蛋白9(HSPA9)将耐药性传播给BTZ敏感的MM细胞的机制。

方法

通过纳米颗粒跟踪分析和透射电子显微镜鉴定血清外泌体。采用液相色谱-质谱联用和公共数据库筛选外泌体HSPA9。使用细胞计数试剂盒-8、蛋白质印迹法和集落形成试验检测HSPA9蛋白在体外的作用。采用免疫共沉淀、免疫荧光和蛋白质截短试验确定HSPA9-USP1-TRIP13复合物的调控网络。进行体内光学成像和异种移植小鼠模型研究外泌体HSPA9促进MM增殖和BTZ耐药性。

结果

我们证明HSPA9在血清外泌体和BTZ耐药的MM患者中高表达。敲低HSPA9可显著抑制体外肿瘤发生并逆转BTZ耐药性。作为HSPA9的下游分子,甲状腺激素受体相互作用蛋白13(TRIP13)在BTZ耐药的MM患者中也高表达。机制上,HSPA9的羧基末端肽结合结构域为招募去泛素化酶泛素特异性肽酶1(USP1)提供了一个平台,从而防止TRIP13蛋白降解。HSPA9-USP1-TRIP13复合物在细胞质中表现出稳定性,其抑制作用显著增强体外BTZ耐药性。

结论

我们的研究结果提出了一个开创性的分子调控网络,其中MM细胞来源的外泌体HSPA9通过USP1/TRIP13信号通路传递BTZ耐药性。这项研究突出了外泌体HSPA9作为克服MM细胞BTZ耐药性的一个有前景的靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a8e1/11948694/e8926405f79c/12964_2025_2158_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验